Sarepta Therapeutics Inc (SRPT)

61.41
0.43 0.71
NASDAQ : Health Care
Prev Close 60.98
Open 61.17
Day Low/High 59.60 / 62.23
52 Wk Low/High 8.00 / 41.97
Volume 2.46M
Avg Volume 4.12M
Exchange NASDAQ
Shares Outstanding 47.90M
Market Cap 2.92B
EPS -5.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ("Catabasis"), and Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping

Sarepta Therapeutics Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne...

Selling Into Strength Can Be a Great Strategic Move

We are seeing lower lows in the indices as I write.

Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys

Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys

Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.

There's No Debate, Dip Buyers Are Jittery

There's No Debate, Dip Buyers Are Jittery

If the market is looking to correct, election worries are a convenient excuse.

For Traders, Planning Is More Important Than the Plan

For Traders, Planning Is More Important Than the Plan

Because every stock has a unique personality that requires its own strategy.

Shark Bites: Stock Picking Makes a Comeback

Market ends the week with some profit-taking.

Sarepta Therapeutics Announces Pricing Of $300 Million Public Offering Of Common Stock

Sarepta Therapeutics Announces Pricing Of $300 Million Public Offering Of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.

Closing Bell: Yahoo! Confirms 2014 Hack; Nasdaq Clocks New Record

Closing Bell: Yahoo! Confirms 2014 Hack; Nasdaq Clocks New Record

Relief over the Federal Reserve's slow-and-steady rates plans fueled another day of gains on Thursday.

Stocks Rise as Wall Street Cheers Fed's Patience on Interest Rates

Stocks Rise as Wall Street Cheers Fed's Patience on Interest Rates

Stocks rise Thursday as relief over a patient Federal Reserve fuels market gains.

I Am One of the Underinvested Bulls Right Now

I Am One of the Underinvested Bulls Right Now

It's challenging to put cash to work but I'll keep digging.

Stock Futures Rise as Wall Street Finds Relief in a Patient Fed

Stock Futures Rise as Wall Street Finds Relief in a Patient Fed

Stock futures move higher on Thursday as relief over a patient Federal Reserve fuels market gains for a second day.

Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering

Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering

Sarepta (SRPT) disclosed a public offering worth up to $225 million after Wednesday's closing bell.

Sarepta Therapeutics Announces Proposed Public Offering Of Common Stock

Sarepta Therapeutics Announces Proposed Public Offering Of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in...

Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling

Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling

BioMarin (BMRN) announced today that it would seek further review of a Patent Trial and Appeal Board ruling over Sarepta's (SRPT) Duchenne muscular dystrophy drug.

Sarepta Therapeutics Announces Favorable USPTO Decisions In Exon 51 And Exon 53 Composition Of Matter Patent Interference Cases Against BioMarin Pharmaceutical

Sarepta Therapeutics Announces Favorable USPTO Decisions In Exon 51 And Exon 53 Composition Of Matter Patent Interference Cases Against BioMarin Pharmaceutical

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has...

Jim Cramer: Sarepta Could Be a Takeover Target, but I'm Not Buying Shares

Jim Cramer: Sarepta Could Be a Takeover Target, but I'm Not Buying Shares

Shares of drug-maker Sarepta are higher Tuesday on the back of an upgrade from RBC, but Jim Cramer says he's not adding shares to his portfolio.

Sarepta Therapeutics Shares Buoyed by RBC Upgrade

Sarepta Therapeutics Shares Buoyed by RBC Upgrade

Analysts say the Duchenne muscular-dystrophy treatment could be a "major game changer" for Sarepta Therapeutics.

Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval

Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval

Sarepta Therapeutics' (SRPT) Exondys drug for Duchenne muscular dystrophy was approved by the FDA yesterday, prompting Cowen to raise its rating on the stock to 'outperform' today.

These Biotech Names Are on My Radar

These Biotech Names Are on My Radar

But I'm expecting that things will slow into the Fed news.

Morning Movers: CHK, WFC, SRPT

Morning Movers: CHK, WFC, SRPT

Billionaire activist investor Carl Icahn helped pull down Chesapeake Energy by unveiling a substantial selloff.

Analysts' Actions -- HD Supply, JD.com, Sarepta, Wells Fargo and More

Analysts' Actions -- HD Supply, JD.com, Sarepta, Wells Fargo and More

Here are Tuesday's top research calls, including upgrades for Wells Fargo and Sarepta, and downgrades for HD Supply and JD.com.

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Cramer sees Anadarko Petroleum profiting and Coach returning to its former glory.

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Worried about a bad event? There will be money coming off the sidelines afterward. Be prepared to buy on weakness.

Sarepta (SRPT) Stock Upgraded on DMD Drug Approval

Sarepta (SRPT) Stock Upgraded on DMD Drug Approval

The FDA provided accelerated approval to Sarepta's (SRPT) Duchenne muscular dystrophy drug and several firms consequently raised the stock's rating.

Market Slows Down, Waiting for Wednesday

Market Slows Down, Waiting for Wednesday

Concerns are starting to pop up that maybe the Fed statement will have a hawkish tone.